# Cincinnati Children’s

> Cincinnati Children’s is a VC fund backing Health Care and Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cincinnati, United States
- Total investments: 11
- Last investment: Nov 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cincinnati-children's-hospital-medical-center
- X (Twitter): http://twitter.com/CincyChildrens
- Website: http://cincinnatichildrens.org
- Facebook: http://www.facebook.com/cincinnatichildrensfans

Cincinnati Children’s is a VC fund in Cincinnati focused on Health Care and Biotechnology. Patients and families from across the region and around the world come to Cincinnati Children’s Hospital Medical Center because we are dedicated to improving child health. Other medical providers often turn to us when a child needs a complex surgical procedure or treatment for a rare pediatric disease. We discover new and better ways to treatthe conditions that affect children, maintaining our status as one of the world’s foremost centers for pediatric care.

## Contacts

5 contacts available for Cincinnati Children’s. Shizune tracks 6 team members at Cincinnati Children’s. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cincinnati-childrens?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 45% |
| Biotechnology | 3 | 27% |
| Medical Device | 3 | 27% |
| Pharmaceutical | 3 | 27% |
| Medical | 1 | 9% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 36% |
| Series A | 2 | 18% |
| Series B | 2 | 18% |
| Series D | 1 | 9% |
| Funding Round | 1 | 9% |

6 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andrew Herr | Director of Admissions, Immunology PhD Progam; Professor | 0 | — |
| David Moore | Director, Communication Scineces Research Center | 0 | — |
| James Heubi | Professor of Department of Pediatrics | 0 | — |
| Margaret Collins | Professor of Pediatrics & Pathologist | 0 | — |
| Margaret Hostetter | Professor of Pediatrics; Editor-in-Chief, Current Opinion in Pediatrics | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hippocratic AI | Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $126M | Series C | Nov 03, 2025 |  |
| Hippocratic AI | Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $53M | Series A | Mar 18, 2024 |  |
| STAQ Pharma | STAQ Pharma offers safety, transparency, availability, and quality to compounded medications. It features Onsite production of non-sterile to sterile solutions. And sterile-to-sterile repackaging. Inventory systems to forecast needs and proactively provide partners with critical products.It was founded in 2018 and headquartered in Denver,Colorado. |  | Series C | Mar 02, 2022 |  |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $215M | Series C | Jan 27, 2022 |  |
| Airway Therapeutics | Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $15.5M | Series C | Dec 05, 2019 |  |
| Enable Injections | Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $50M | Series B | Oct 25, 2018 |  |
| Airway Therapeutics | Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $10.9M | Series B | Mar 13, 2018 |  |
| Airway Therapeutics | Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $6.3M |  | Mar 06, 2017 |  |
| Airway Therapeutics | Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $6.4M | Convertible Note | Mar 06, 2017 |  |
| Assurerx Health | Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $37.4M | Series D | Dec 23, 2014 |  |

10 of 11 investments shown.

## Co-investors
- [CincyTech](https://shizune.co/investors/profile/cincytech) — VC Fund, 6 deals together
- [Danmar Capital](https://shizune.co/investors/profile/danmar-capital) — VC Fund, 4 deals together
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund, 4 deals together
- [Queen City Angels](https://shizune.co/investors/profile/queen-city-angels) — VC Fund, 4 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 3 deals together
- Cintrifuse — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Cincinnati Children’s invest in?

Cincinnati Children’s invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cincinnati Children’s?

Public channels for Cincinnati Children’s include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cincinnati Children’s?

The team at Cincinnati Children’s includes Andrew Herr (Director of Admissions, Immunology PhD Progam; Professor), David Moore (Director, Communication Scineces Research Center) and James Heubi (Professor of Department of Pediatrics), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co